[Therapy-induced sensitization in the treatment of ulcus cruris].
D000166:Acridines / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000891:Anti-Infective Agents, Local / Q000009:adverse effects*; D001566:Benzocaine / Q000009:adverse effects; D002701:Chloramphenicol / Q000009:adverse effects; D004342:Drug Hypersensitivity; D004485:Eczema / Q000139:chemically induced; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy*; D009583:Nitrofurazone / Q000009:adverse effects; D012871:Skin Diseases / Q000139:chemically induced; D013424:Sulfanilamides / Q000009:adverse effects
D000166:Acridines; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D013424:Sulfanilamides; D002701:Chloramphenicol; D001566:Benzocaine; D009583:Nitrofurazone
Therapiebedingte Sensibilisierungenbei der Behandlung des Ulcus cruris.